{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:44:22Z","timestamp":1769049862583,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900109"],"award-info":[{"award-number":["81900109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Innovative Talents Subsidized Project","award":["(2019)30357"],"award-info":[{"award-number":["(2019)30357"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05856-z","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T09:03:37Z","timestamp":1719479017000},"page":"3239-3242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib"],"prefix":"10.1007","volume":"103","author":[{"given":"Yuemin","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-5897","authenticated-orcid":false,"given":"Guangsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"issue":"15","key":"5856_CR1","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1182\/blood.2021010898","volume":"137","author":"C Gurnari","year":"2021","unstructured":"Gurnari C, Maciejewski JP (2021) How I manage acquired pure red cell aplasia in adults [J]. Blood 137(15):2001\u20132009","journal-title":"Blood"},{"issue":"6","key":"5856_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.13376","volume":"169","author":"M Hirokawa","year":"2015","unstructured":"Hirokawa M, Sawada K, Fujishima N et al (2015) Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004\/2006 by the Japan PRCA collaborative study group [J]. Br J Haematol 169(6):879\u2013886","journal-title":"Br J Haematol"},{"issue":"21","key":"5856_CR3","doi-asserted-by":"publisher","first-page":"6451","DOI":"10.1182\/bloodadvances.2023010587","volume":"7","author":"H Lobbes","year":"2023","unstructured":"Lobbes H, Lega JC, Le Guenno G et al (2023) Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis [J]. Blood Adv 7(21):6451\u20136465","journal-title":"Blood Adv"},{"issue":"3","key":"5856_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.amjms.2023.06.009","volume":"366","author":"RT Means Jr","year":"2023","unstructured":"Means RT Jr (2023) Pure red cell aplasia: the second hundred years [J]. Am J Med Sci 366(3):160\u2013166","journal-title":"Am J Med Sci"},{"issue":"7","key":"5856_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00277-022-04847-2","volume":"101","author":"X Wu","year":"2022","unstructured":"Wu X, Cheng L, Liu X et al (2022) Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia [J]. Ann Hematol 101(7):1493\u20131498","journal-title":"Ann Hematol"},{"issue":"3","key":"5856_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00277-020-03926-6","volume":"99","author":"X Liu","year":"2020","unstructured":"Liu X, Lu X, Chen L et al (2020) Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective [J]. Ann Hematol 99(3):443\u2013449","journal-title":"Ann Hematol"},{"issue":"2","key":"5856_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3324\/haematol.2017.175810","volume":"103","author":"SK Balasubramanian","year":"2018","unstructured":"Balasubramanian SK, Sadaps M, Thota S et al (2018) Rational management approach to pure red cell aplasia [J]. Haematologica 103(2):221\u2013230","journal-title":"Haematologica"},{"issue":"5","key":"5856_CR8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41375-022-01532-1","volume":"36","author":"Y Huang","year":"2022","unstructured":"Huang Y, Chen M, Yang C et al (2022) Sirolimus is effective for refractory\/relapsed\/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial [J]. Leukemia 36(5):1351\u20131360","journal-title":"Leukemia"},{"issue":"11","key":"5856_CR9","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00277-018-3431-5","volume":"97","author":"Z Long","year":"2018","unstructured":"Long Z, Yu F, Du Y et al (2018) Successful treatment of refractory\/relapsed acquired pure red cell aplasia with sirolimus [J]. Ann Hematol 97(11):2047\u20132054","journal-title":"Ann Hematol"},{"issue":"9","key":"5856_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis [J]. N Engl J Med 366(9):799\u2013807","journal-title":"N Engl J Med"},{"issue":"5","key":"5856_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera [J]. N Engl J Med 372(5):426\u2013435","journal-title":"N Engl J Med"},{"key":"5856_CR12","doi-asserted-by":"publisher","first-page":"954268","DOI":"10.3389\/fimmu.2022.954268","volume":"13","author":"S Fan","year":"2022","unstructured":"Fan S, Huo WX, Yang Y et al (2022) Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis [J]. Front Immunol 13:954268","journal-title":"Front Immunol"},{"issue":"24","key":"5856_CR13","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood.2021014860","volume":"139","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhao YZ, Ma HH et al (2022) A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis [J]. Blood 139(24):3493\u20133504","journal-title":"Blood"},{"issue":"3","key":"5856_CR14","first-page":"8","volume":"28","author":"N Kashetsky","year":"2023","unstructured":"Kashetsky N, Turchin I (2023) Utilization of Topical Ruxolitinib in Dermatology: a review [J]. Skin Therapy Lett 28(3):8\u201313","journal-title":"Skin Therapy Lett"},{"key":"5856_CR15","doi-asserted-by":"crossref","unstructured":"Horna P, Shi M, Olteanu H et al (2021) Emerging role of T-cell receptor constant \u03b2 Chain-1 (TRBC1) expression in the Flow Cytometric diagnosis of T-cell malignancies [J]. Int J Mol Sci, 22(4)","DOI":"10.3390\/ijms22041817"},{"issue":"2","key":"5856_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12185-018-2446-y","volume":"108","author":"X Wu","year":"2018","unstructured":"Wu X, Wang S, Lu X et al (2018) Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center [J]. Int J Hematol 108(2):123\u2013129","journal-title":"Int J Hematol"},{"issue":"41","key":"5856_CR17","doi-asserted-by":"publisher","first-page":"e17425","DOI":"10.1097\/MD.0000000000017425","volume":"98","author":"X Wu","year":"2019","unstructured":"Wu X, Yang Y, Lu X et al (2019) Induced complete remission faster in adult patients with acquired pure red cell aplasia by combining cyclosporine A with corticosteroids [J]. Med (Baltim) 98(41):e17425","journal-title":"Med (Baltim)"},{"issue":"20","key":"5856_CR18","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","volume":"366","author":"HL Koskela","year":"2012","unstructured":"Koskela HL, Eldfors S, Ellonen P et al (2012) Somatic STAT3 mutations in large granular lymphocytic leukemia [J]. N Engl J Med 366(20):1905\u20131913","journal-title":"N Engl J Med"},{"issue":"3","key":"5856_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1172\/JCI9940","volume":"107","author":"PK Epling-Burnette","year":"2001","unstructured":"Epling-Burnette PK, Liu JH, Catlett-Falcone R et al (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression [J]. J Clin Invest 107(3):351\u2013362","journal-title":"J Clin Invest"},{"issue":"4","key":"5856_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/ajh.20374","volume":"79","author":"M Masuda","year":"2005","unstructured":"Masuda M, Teramura M, Matsuda A et al (2005) Clonal T cells of pure red-cell aplasia [J]. Am J Hematol 79(4):332\u2013333","journal-title":"Am J Hematol"},{"issue":"20","key":"5856_CR21","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1182\/bloodadvances.2018022723","volume":"2","author":"T Kawakami","year":"2018","unstructured":"Kawakami T, Sekiguchi N, Kobayashi J et al (2018) Frequent STAT3 mutations in CD8\u2009+\u2009T cells from patients with pure red cell aplasia [J]. Blood Adv 2(20):2704\u20132712","journal-title":"Blood Adv"},{"issue":"12","key":"5856_CR22","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/leu.2015.280","volume":"29","author":"B Bilori","year":"2015","unstructured":"Bilori B, Thota S, Clemente MJ et al (2015) Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia [J]. Leukemia 29(12):2427\u20132429","journal-title":"Leukemia"},{"key":"5856_CR23","doi-asserted-by":"crossref","unstructured":"Marchand T, Pastoret C, Damaj G et al (2024) Efficacy of ruxolitinib in the treatment of relapsed\/refractory large granular lymphocytic leukaemia [J]. Br J Haematol","DOI":"10.1111\/bjh.19476"},{"issue":"1","key":"5856_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood.2022015898","volume":"141","author":"EM Groarke","year":"2023","unstructured":"Groarke EM, Feng X, Aggarwal N et al (2023) Efficacy of JAK1\/2 inhibition in murine immune bone marrow failure [J]. Blood 141(1):72\u201389","journal-title":"Blood"},{"issue":"6","key":"5856_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1182\/blood.2020006075","volume":"136","author":"LK Meyer","year":"2020","unstructured":"Meyer LK, Verbist KC, Albeituni S et al (2020) JAK\/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation [J]. Blood 136(6):657\u2013668","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05856-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05856-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05856-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:10:50Z","timestamp":1722060650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05856-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5856"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05856-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"8 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Written informed consent was obtained from the patient for ruxolitinib treatment and for data collection and publication. The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}